Active, not recruitingPHASE1, PHASE2NCT04551131
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Melissa Hines, MDSt. Jude Children's Research Hospital
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 22 years · All sexes
- Timeline
- 2021 – 2026
Study locations (13)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Children's Hospital of Orange County, Orange, California, United States
- University of California San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- John Hopkins University, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Cohen Children's Medical Center, New Hyde Park, New York, United States
- Levine Children's Hospital, Charlotte, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- Children's Wisconsin/Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Collaborators
Incyte Corporation · North American Consortium for Histiocytosis · Cures Within Reach
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04551131 on ClinicalTrials.govOther trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07525466Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)Beijing Tongren Hospital
- RECRUITINGPHASE4NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07488728Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisBeijing Children's Hospital
- RECRUITINGPHASE2NCT06160791Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Jerry Lee, MD, MSc, MPhil
- ACTIVE NOT RECRUITINGNCT06587191Emapalumab Efficacy in Children With Primary Hemophagocytic LymphohistiocytosisFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGNCT06339177Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE StudyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06614998Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective StudyThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGNCT06585124Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasFondazione Policlinico Universitario Agostino Gemelli IRCCS
See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease →